Download image:
919-541-6996

Josephine A. Mauskopf

Vice President of Health Economics, RTI-HS

Josephine Mauskopf, PhD, MHA, has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmacoeconomic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, bipolar disease, breast cancer, and HIV infection. She has estimated the cost-effectiveness of antiretroviral drugs, as well as drugs for treating herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community-acquired pneumonia, intra-abdominal infections, and primary pulmonary hypertension. Dr. Mauskopf was previously vice president at MEDTAP International, department head of Economics Research at Burroughs Wellcome, and director of Pharmacoeconomics Research for anti-virals and anti-infectives at Glaxo Wellcome. She completed 8 years as editor in chief of Value in Health. She has presented her research at numerous national and international symposia, and has published extensively in journals.

Education

PhD, Economics, Duke University; MHA, Health Administration, Duke University; MA, Physiology and Pharmacology, Duke University.

Latest Publications

Schaller, S., Mauskopf, J., Kriza, C., Wahlster, P., & Kolominsky-Rabas, P.L. (2015). The main cost drivers in dementia: A systematic review. International Journal of Geriatric Psychiatry, 30 (2):111-129.
Brennan, V.K., Mauskopf, J., Colosia, A.D., Copley-Merriman, C., Hass, B., & Palencia, R. (2015). Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: A systematic review. Expert Review of Pharmacoeconomics & Outcomes Research, 15 (1):111-123.
Talbird, S.E., Graham, J., Mauskopf, J., Masseria, C., & Krishnarajah, G. (2015). Impact of tetanus, diphtheria, and acellular pertussis (tdap) vaccine use in wound management on health care costs and pertussis cases. J Manag Care Spec Pharm , 21 (1):88-99.
Williams, P., Mauskopf, J., Lebiecki, J., & Kilburg, A. (2014). Using multicriteria decision analysis during drug development to predict reimbursement decisions. Journal of Market Access & Health Policy, 2 :Article No. 25270.
Standaert, B., Ethgen, O., Emerson, R., Postma, M., & Mauskopf, J. (2014). Comparing Cost-Effectiveness Results for a Vaccine Across Different Countries Worldwide: What Can We Learn?. Advances in Therapy, 31 (10):1095-1108.
View all publications by Josephine A. Mauskopf (201)

Expertise

  • Health Economics
  • Burden of Illness Literature Reviews
  • Economic Analyses of Health Care Interventions
  • Health Policy Analyses